{"links": [{"source": 0, "target": "t1464", "value": "None"}, {"source": 0, "target": "t1471", "value": "None"}, {"source": 0, "target": "t1439", "value": "None"}, {"source": 0, "target": "t1456", "value": "None"}, {"source": 0, "target": "t1446", "value": "None"}, {"source": 0, "target": "t1475", "value": "None"}, {"source": 0, "target": "t1463", "value": "None"}, {"source": "t1439", "target": "t1441", "value": "None"}, {"source": "t1439", "target": "t1440", "value": "None"}, {"source": "t1439", "target": "t1442", "value": "None"}, {"source": "t1456", "target": "t1457", "value": "None"}, {"source": "t1456", "target": "t1462", "value": "None"}, {"source": "t1446", "target": "t1449", "value": "None"}, {"source": "t1446", "target": "t1448", "value": "None"}, {"source": "t1446", "target": "t1450", "value": "None"}, {"source": "t1446", "target": "t1447", "value": "None"}, {"source": "t1475", "target": "t1480", "value": "None"}, {"source": "t1475", "target": "t1481", "value": "None"}, {"source": "t1475", "target": "t1476", "value": "None"}, {"source": "t1463", "target": "t1465", "value": "None"}, {"source": "t1463", "target": "t1466", "value": "None"}, {"source": "t1463", "target": "t1473", "value": "None"}, {"source": "t1463", "target": "t1474", "value": "None"}, {"source": "t1463", "target": "t1467", "value": "None"}, {"source": "t1463", "target": "t1472", "value": "None"}, {"source": "t1441", "target": "t1443", "value": "None"}, {"source": "t1457", "target": "t1458", "value": "None"}, {"source": "t1449", "target": "t1452", "value": "None"}, {"source": "t1449", "target": "t1454", "value": "None"}, {"source": "t1449", "target": "t1451", "value": "None"}, {"source": "t1449", "target": "t1453", "value": "None"}, {"source": "t1449", "target": "t1455", "value": "None"}, {"source": "t1476", "target": "t1477", "value": "None"}, {"source": "t1467", "target": "t1468", "value": "None"}, {"source": "t1467", "target": "t1469", "value": "None"}, {"source": "t1467", "target": "t1470", "value": "None"}, {"source": "t1443", "target": "t1445", "value": "None"}, {"source": "t1443", "target": "t1444", "value": "None"}, {"source": "t1458", "target": "t1459", "value": "None"}, {"source": "t1455", "target": "d181", "value": "None"}, {"source": "t1477", "target": "t1478", "value": "None"}, {"source": "t1459", "target": "t1461", "value": "None"}, {"source": "t1459", "target": "t1460", "value": "None"}, {"source": "t1459", "target": "d171", "value": "None"}, {"source": "t1459", "target": "d224", "value": "None"}, {"source": "t1478", "target": "t1479", "value": "None"}, {"source": "t1478", "target": "d410", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Peripheral_circulatory_conditions", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Peripheral_circulatory_conditions"}}, {"category": "treatment", "id": "t1464", "name": "strategy, policy and commissioning", "draggable": "true", "value": {"name": "strategy, policy and commissioning", "type": "information and support", "time": "", "intention": "", "description": "title:strategy, policy and commissioning", "drug": {}}}, {"category": "treatment", "id": "t1471", "name": "local services: areas of work", "draggable": "true", "value": {"name": "local services: areas of work", "type": "information and support", "time": "", "intention": "", "description": "title:local services: areas of work", "drug": {}}}, {"category": "treatment", "id": "t1439", "name": "person at risk of cardiovascular disease", "draggable": "true", "value": {"name": "person at risk of cardiovascular disease", "type": "treatment related", "time": "", "intention": "", "description": "title:person at risk of cardiovascular disease", "drug": {}}}, {"category": "treatment", "id": "t1456", "name": "person with suspected lower limb peripheral arterial disease, with or without symptoms", "draggable": "true", "value": {"name": "person with suspected lower limb peripheral arterial disease, with or without symptoms", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with suspected lower limb peripheral arterial disease, with or without symptoms", "drug": {}}}, {"category": "treatment", "id": "t1446", "name": "diet", "draggable": "true", "value": {"name": "diet", "type": "information and support", "time": "", "intention": "", "description": "title:diet", "drug": {}}}, {"category": "treatment", "id": "t1475", "name": "adult with suspected type 1 diabetes", "draggable": "true", "value": {"name": "adult with suspected type 1 diabetes", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with suspected type 1 diabetes", "drug": {}}}, {"category": "treatment", "id": "t1463", "name": "encouraging physical activity", "draggable": "true", "value": {"name": "encouraging physical activity", "type": "information and support", "time": "", "intention": "", "description": "title:encouraging physical activity", "drug": {}}}, {"category": "treatment", "id": "t1441", "name": "identification and assessment", "draggable": "true", "value": {"name": "identification and assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:identification and assessment", "drug": {}}}, {"category": "treatment", "id": "t1440", "name": "people at risk of dying early from cardiovascular disease", "draggable": "true", "value": {"name": "people at risk of dying early from cardiovascular disease", "type": "treatment related", "time": "", "intention": "", "description": "title:people at risk of dying early from cardiovascular diseasehead:People at risk of dying early from cardiovascular diseaseSee what NICE says on identifying and supporting people most at risk of dying early from cardiovascular disease. These recommendations aim to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.The recommendations cover adults who are disadvantaged: who smoke and/or who are eligible for statins and/or who are at high risk of CVD due to other factors.", "drug": {}}}, {"category": "treatment", "id": "t1442", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t1457", "name": "assessment and diagnosis", "draggable": "true", "value": {"name": "assessment and diagnosis", "type": "information and support", "time": "", "intention": "", "description": "title:assessment and diagnosishead:Assessment and diagnosisAssess people for the presence of peripheral arterial disease if they: have symptoms suggestive of peripheral arterial disease or have diabetes, non-healing wounds on the legs or feet or unexplained leg pain or are being considered for interventions to the leg or foot or need to use compression hosiery.Assess people with suspected peripheral arterial disease by:  asking about the presence and severity of possible symptoms of intermittent claudication and critical limb ischaemia examining the legs and feet for evidence of critical limb ischaemia, for example ulceration examining the femoral, popliteal and foot pulses measuring the ankle brachial pressure index (see below). Measure the ankle brachial pressure index in the following way:  The person should be resting and supine if possible.  Record systolic blood pressure with an appropriately sized cuff in both arms and in the posterior tibial, dorsalis pedis and, where possible, peroneal arteries. Take measurements manually using a doppler probe of suitable frequency in preference to an automated system. Document the nature of the doppler ultrasound signals in the foot arteries. Calculate the index in each leg by dividing the highest ankle pressure by the highest arm pressure.subhead:People with diabetesDo not exclude a diagnosis of peripheral arterial disease in people with diabetes based on a normal or raised ankle brachial pressure index alone.Do not use pulse oximetry for diagnosing peripheral arterial disease in people with diabetes. See why we made the recommendations on diagnosis in people with diabetes.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Identification and assessment of peripheral arterial diseaseSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG147", "drug": {}}}, {"category": "treatment", "id": "t1462", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t1449", "name": "settings", "draggable": "true", "value": {"name": "settings", "type": "information and support", "time": "", "intention": "", "description": "title:settings", "drug": {}}}, {"category": "treatment", "id": "t1448", "name": "training", "draggable": "true", "value": {"name": "training", "type": "information and support", "time": "", "intention": "", "description": "title:training", "drug": {}}}, {"category": "treatment", "id": "t1450", "name": "lifestyle advice", "draggable": "true", "value": {"name": "lifestyle advice", "type": "information and support", "time": "", "intention": "", "description": "title:lifestyle advice", "drug": {}}}, {"category": "treatment", "id": "t1447", "name": "strategy and policy", "draggable": "true", "value": {"name": "strategy and policy", "type": "information and support", "time": "", "intention": "", "description": "title:strategy and policy", "drug": {}}}, {"category": "treatment", "id": "t1480", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t1481", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t1476", "name": "diagnosis", "draggable": "true", "value": {"name": "diagnosis", "type": "treatment related", "time": "", "intention": "", "description": "title:diagnosishead:DiagnosisDiagnose type 1 diabetes on clinical grounds in adults presenting with hyperglycaemia, bearing in mind that people with type 1 diabetes typically (but not always) have one or more of: ketosis  rapid weight loss age of onset below 50 years BMI below 25 kg/m2 personal and/or family history of autoimmune disease.Do not discount a diagnosis of type 1 diabetes if an adult presents with a BMI of 25 kg/m2 or above or is aged 50 years or above.Do not measure C-peptide and/or diabetes-specific autoantibody titres routinely to confirm type 1 diabetes in adults. Consider further investigation in adults that involves measurement of C-peptide and/or diabetes-specific autoantibody titres if: type 1 diabetes is suspected but the clinical presentation includes some atypical features (for example, age 50 years or above, BMI of 25 kg/m2 or above, slow evolution of hyperglycaemia or long prodrome) or type 1 diabetes has been diagnosed and treatment started but there is a clinical suspicion that the person may have a monogenic form of diabetes, and C-peptide and/or autoantibody testing may guide the use of genetic testing or classification is uncertain, and confirming type 1 diabetes would have implications for availability of therapy (for example, continuous subcutaneous insulin infusion [CSII or  insulin pump ] therapy). When measuring C-peptide and/or diabetes-specific autoantibody titres, take into account that: autoantibody tests have their lowest false negative rate at the time of diagnosis, and that the false negative rate rises thereafter C-peptide has better discriminative value the longer the test is done after diagnosis with autoantibody testing, carrying out tests for 2 different diabetes-specific autoantibodies, with at least 1 being positive, reduces the false negative rate.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG17", "drug": {}}}, {"category": "treatment", "id": "t1465", "name": "training", "draggable": "true", "value": {"name": "training", "type": "information and support", "time": "", "intention": "", "description": "title:training", "drug": {}}}, {"category": "treatment", "id": "t1466", "name": "workplaces", "draggable": "true", "value": {"name": "workplaces", "type": "information and support", "time": "", "intention": "", "description": "title:workplaces", "drug": {}}}, {"category": "treatment", "id": "t1473", "name": "lifestyle advice on diet and physical activity", "draggable": "true", "value": {"name": "lifestyle advice on diet and physical activity", "type": "information and support", "time": "", "intention": "", "description": "title:lifestyle advice on diet and physical activity", "drug": {}}}, {"category": "treatment", "id": "t1474", "name": "walking and cycling", "draggable": "true", "value": {"name": "walking and cycling", "type": "information and support", "time": "", "intention": "", "description": "title:walking and cycling", "drug": {}}}, {"category": "treatment", "id": "t1467", "name": "nhs and public health services", "draggable": "true", "value": {"name": "nhs and public health services", "type": "information and support", "time": "", "intention": "", "description": "title:nhs and public health serviceshead:NHS and public health servicesSee NICE s recommendations on behaviour change.", "drug": {}}}, {"category": "treatment", "id": "t1472", "name": "schools", "draggable": "true", "value": {"name": "schools", "type": "information and support", "time": "", "intention": "", "description": "title:schools", "drug": {}}}, {"category": "treatment", "id": "t1443", "name": "cardiovascular disease prevention", "draggable": "true", "value": {"name": "cardiovascular disease prevention", "type": "treatment related", "time": "", "intention": "", "description": "title:cardiovascular disease prevention", "drug": {}}}, {"category": "treatment", "id": "t1458", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportOffer all people with peripheral arterial disease oral and written information about their condition. Discuss it with them so they can share decision-making, and understand the course of the disease and what they can do to help prevent disease progression. Information should include:  the causes of their symptoms and the severity of their disease the risks of limb loss and/or cardiovascular events associated with peripheral arterial disease the key modifiable risk factors, such as smoking, control of diabetes, hyperlipidaemia, diet, body weight and exercise (see also information about secondary prevention of cardiovascular disease) how to manage pain all relevant treatment options, including the risks and benefits of each how they can access support for dealing with depression and anxiety.Ensure that information, tailored to the individual needs of the person, is available at diagnosis and subsequently as required, to allow people to make decisions throughout the course of their treatment.NICE has written information for the public on peripheral arterial disease. NICE has produced guidance on the components of good patient experience in adult NHS services. Follow NICE s recommendations on patient experience in adult NHS services. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG147", "drug": {}}}, {"category": "treatment", "id": "t1452", "name": "community and leisure services", "draggable": "true", "value": {"name": "community and leisure services", "type": "information and support", "time": "", "intention": "", "description": "title:community and leisure services", "drug": {}}}, {"category": "treatment", "id": "t1454", "name": "schools and childcare", "draggable": "true", "value": {"name": "schools and childcare", "type": "information and support", "time": "", "intention": "", "description": "title:schools and childcare", "drug": {}}}, {"category": "treatment", "id": "t1451", "name": "primary care", "draggable": "true", "value": {"name": "primary care", "type": "cancer ralated", "time": "", "intention": "", "description": "title:primary care", "drug": {}}}, {"category": "treatment", "id": "t1453", "name": "commercial organisations", "draggable": "true", "value": {"name": "commercial organisations", "type": "treatment related", "time": "", "intention": "", "description": "title:commercial organisationshead:Commercial organisations, including manufacturing, retailing, catering and weight managementsubhead:Manufacturers of products for womenFolic acidManufacturers should include information with their products on the importance of folic acid supplements before and during pregnancy. Relevant products may include pregnancy tests, sanitary products, contraceptives and ovulation predictor kits. Vitamin DFor advice for manufacturers on vitamin D supplements, see NICE s recommendations on vitamin D: supplement use in specific population groups. subhead:Take-aways and other food outlets See recommendations on standards for take-aways and other food outlets. subhead:Providers of weight management programmesSee recommendations on weight management programmes.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. PH11", "drug": {}}}, {"category": "treatment", "id": "t1455", "name": "all workplaces", "draggable": "true", "value": {"name": "all workplaces", "type": "information and support", "time": "", "intention": "commit\nnicotine oral chewing gum and lozenges are used to help you stop smoking. nicotine is absorbed from the gum or lozenge in the mouth and enters the blood stream. this replaces the nicotine you would get from smoking and makes the withdrawal effects from not smoking less severe. the amount of nicotine is decreased over time until use is stopped.\nalthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. in these cases, your doctor may want to change the dose, or other precautions may be necessary. tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [otc]) medicine.", "description": "title:all workplaceshead:Workplaces, including the NHS and local authoritiessubhead:Overarching recommendationAll workplaces, particularly large organisations such as the NHS and local authorities, should address the prevention and management of obesity, because of the considerable impact on the health of the workforce and associated costs to industry. Workplaces are encouraged to collaborate with local partnerships and to ensure that action is in line with the local obesity strategy (in England).subhead:For all workplacesWorkplaces should provide opportunities for staff to eat a healthy diet and be more physically active, through:  active and continuous promotion of healthy choices in restaurants, hospitality, vending machines and shops for staff and clients, in line with existing Food Standards Agency guidance working practices and policies, such as active travel policies for staff and visitors.Incentive schemes (such as policies on travel expenses, the price of food and drinks sold in the workplace and contributions to gym membership) that are used in a workplace should be sustained and part of a wider programme to support staff in managing weight, improving diet and increasing activity levels.subhead:For NHS, public organisations and large commercial organisationsWorkplaces providing health checks for staff should ensure that they address weight, diet and activity, and provide ongoing support.Action to improve food and drink provision in the workplace, including restaurants, hospitality and vending machines, should be supported by tailored educational and promotional programmes, such as a behavioural intervention or environmental changes (for example, food labelling or changes to availability).For this to be effective, commitment from senior management, enthusiastic catering management, a strong occupational health lead, links to other on-site health initiatives, supportive pricing policies and heavy promotion and advertisement at point of purchase are likely to be needed.See also recommendations on public sector catering, and recommendations for workplaces  in NICE s recommendations on physical activity.Align actions to improve diet with strategies to prevent obesity at a community level to ensure a coherent, integrated approach (see what NICE says on obesity: working with local communities).subhead:Support for workplaces from health professionalsSupport for workplacesHealth professionals such as occupational health staff and public health practitioners should establish partnerships with local businesses and support the implementation of workplace programmes to prevent and manage obesity.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.Obesity in adults: prevention and lifestyle weight management programmes quality standard2Nutritional information at the point of choosing food and drink optionsObesity in children and young people: prevention and lifestyle weight management programmes quality standard2Nutritional information at the point of choosing food and drink options \u2013 obesity prevention and lifestyle weight management in children and young peopleSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG43", "drug": {"commit": "DB00184"}}}, {"category": "treatment", "id": "t1477", "name": "support and individualised care", "draggable": "true", "value": {"name": "support and individualised care", "type": "information and support", "time": "", "intention": "", "description": "title:support and individualised carehead:Support and individualised careTake account of any disabilities, including visual impairment, when planning and delivering care for adults with type 1 diabetes.Advice to adults with type 1 diabetes should be provided by a range of professionals with skills in diabetes care working together in a coordinated approach. A common environment (diabetes centre) is an important resource in allowing a diabetes multidisciplinary team to work and communicate efficiently while providing consistent advice. Provide adults with type 1 diabetes with: open-access services on a walk-in and telephone-request basis during working hours a helpline staffed by people with specific diabetes expertise on a 24-hour basis contact information for these services.Regard each adult with type 1 diabetes as an individual, rather than as a member of any cultural, economic or health-affected group (see also recommendations about the cultural preferences of individual adults with type 1 diabetes in dietary management and insulin regimens).Use population, practice-based and clinic diabetes registers (as specified by the National service framework for diabetes) to assist programmed recall for annual review and assessment of complications and cardiovascular risk. Also see delivery of care in care in hospital.NICE has written information for the public on type 1 diabetes in adults: diagnosis and management.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG17", "drug": {}}}, {"category": "treatment", "id": "t1468", "name": "people", "draggable": "true", "value": {"name": "people", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people", "drug": {}}}, {"category": "treatment", "id": "t1469", "name": "specific conditions", "draggable": "true", "value": {"name": "specific conditions", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:specific conditions", "drug": {}}}, {"category": "treatment", "id": "t1470", "name": "other areas", "draggable": "true", "value": {"name": "other areas", "type": "information and support", "time": "", "intention": "", "description": "title:other areas", "drug": {}}}, {"category": "treatment", "id": "t1445", "name": "lipid modification therapy", "draggable": "true", "value": {"name": "lipid modification therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:lipid modification therapy", "drug": {}}}, {"category": "treatment", "id": "t1444", "name": "lifestyle changes", "draggable": "true", "value": {"name": "lifestyle changes", "type": "information and support", "time": "", "intention": "", "description": "title:lifestyle changes", "drug": {}}}, {"category": "treatment", "id": "t1459", "name": "secondary prevention of cardiovascular disease", "draggable": "true", "value": {"name": "secondary prevention of cardiovascular disease", "type": "treatment related", "time": "", "intention": "dipyridamole\ndipyridamole is used to prevent blood clots after heart valve replacement surgery.\ndipyridamole may also be used for other purposes not listed in this medication guide.", "description": "title:secondary prevention of cardiovascular diseasehead:Secondary prevention of cardiovascular diseaseOffer all people with peripheral arterial disease information, advice, support and treatment regarding the secondary prevention of cardiovascular disease, in line with published NICE guidance on:  smoking cessation diet, weight management (see obesity) and exercise (see physical activity) lipid modification and statin therapy the prevention, diagnosis and management of diabetes the prevention, diagnosis and management of high blood pressure antiplatelet therapy (see antiplatelets and antiocoagulants in NICE s guidance on myocardial infarction: rehabilitation and preventing further cardiovascular disease).For more information see NICE s recommendations on cardiovascular disease prevention  and familial hypercholesterolaemia.subhead:Clopidogrel and modified-release dipyridamoleThe following recommendations are an extract from NICE technology appraisal guidance on clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events.This guidance applies to people who have had an occlusive vascular event, or who have established peripheral arterial disease. Clopidogrel is recommended as an option to prevent occlusive vascular events: for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease.Treatment with clopidogrel to prevent occlusive vascular events should be started with the least costly licensed preparation.NICE has written information for the public on clopidogrel and modified-release dipyridamole.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.2Comorbidity assessmentSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG147TA210", "drug": {"clopidogrel": "DB00758", "dipyridamole": "DB00975"}}}, {"category": "treatment", "id": "t1478", "name": "early care plan", "draggable": "true", "value": {"name": "early care plan", "type": "information and support", "time": "", "intention": "albumin\nit is used to treat or prevent low blood volume.\nit is used to treat low blood pressure.\nit is used to replace albumin in people with low blood albumin levels.\nit is used to add back fluid after fluid loss.\nit is used to treat shock.", "description": "title:early care planhead:Early care planAt the time of diagnosis (or if necessary after the management of critically decompensated metabolism), the diabetes professional team should develop with and explain to the adult with type 1 diabetes a plan for their early care. To agree such a plan will generally require: medical assessment to: ensure security of diagnosis of type of diabetes ensure appropriate acute care is given when needed review and detect potentially confounding disease and medicines detect adverse vascular risk factors environmental assessment to understand: the social, home, work and recreational circumstances of the person and carers their preferences in nutrition and physical activity other relevant factors, such as substance use cultural and educational assessment to identify prior knowledge and to enable optimal advice and planning about: treatment modalities diabetes education programmes assessment of emotional state to determine the appropriate pace of educationThe results of the assessment should be used to agree a future care plan. Some items of the initial diabetes assessment: acute medical history social, cultural and educational history/lifestyle review complications history/symptoms long-term/recent diabetes history other medical history/systems family history of diabetes/cardiovascular disease medication history/current medicines vascular risk factors smoking general examination weight/BMI foot/eye/vision examination urine albumin excretion/urine protein/serum creatinine psychological wellbeing attitudes to medicine and self-care immediate family and social relationships and availability of informal support.Elements of an individualised and culturally appropriate plan will include: sites and timescales of diabetes education, including nutritional advice (see education and information and dietary management) initial treatment modalities, including guidance on insulin injection and insulin regimens (see insulin therapy for adults with type 1 diabetes) means of self-monitoring and targets (see blood glucose measurement and targets) symptoms, risk and treatment of hypoglycaemia management of special situations, such as driving means and frequency of communication with the diabetes professional team management of cardiovascular risk factors (see managing cardiovascular disease risk in adults with type 1 diabetes) for women of childbearing potential, implications for pregnancy and family planning advice (see what NICE says on diabetes in pregnancy) frequency and content of follow-up consultations, including review of HbA1c levels and experience of hypoglycaemia, and annual review.After the initial plan is agreed, put arrangements in place to implement it without inappropriate delay, and to provide for feedback and modification of the plan over the ensuing weeks. At the time of diagnosis and periodically thereafter, provide adults with type 1 diabetes with up-to-date information about diabetes support groups (local and national), how to contact them and the benefits of membership. Also see associated illness in individual care plan.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG17", "drug": {}}}, {"category": "treatment", "id": "t1461", "name": "managing critical limb ischaemia", "draggable": "true", "value": {"name": "managing critical limb ischaemia", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing critical limb ischaemia", "drug": {}}}, {"category": "treatment", "id": "t1460", "name": "managing intermittent claudication", "draggable": "true", "value": {"name": "managing intermittent claudication", "type": "treatment related", "time": "", "intention": "", "description": "title:managing intermittent claudication", "drug": {}}}, {"category": "treatment", "id": "t1479", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "drug", "id": "d181", "name": "commit", "draggable": "true", "value": {"name": "commit", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d171", "name": "clopidogrel", "draggable": "true", "value": {"name": "clopidogrel", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d224", "name": "dipyridamole", "draggable": "true", "value": {"name": "dipyridamole", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d410", "name": "albumin", "draggable": "true", "value": {"name": "albumin", "time": "None", "period": "None", "dosage": "None"}}]}